Division of Gastroenterology, Nutrition and Hepatology, Boston Children’s Hospital, Boston, United States; Department of Pediatrics, Harvard Medical School, Boston, United States
Matija Hedl
Department of Medicine, Yale University, New Haven, United States
Jie Yan
Department of Medicine, Yale University, New Haven, United States
Tao Zuo
Division of Gastroenterology, Nutrition and Hepatology, Boston Children’s Hospital, Boston, United States; Department of Pediatrics, Harvard Medical School, Boston, United States
Tian-Min Fu
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States; Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, United States
Xiaomo Jiang
Novartis Institutes for Biomedical Research, Cambridge, United States
Jay R Thiagarajah
Division of Gastroenterology, Nutrition and Hepatology, Boston Children’s Hospital, Boston, United States; Department of Pediatrics, Harvard Medical School, Boston, United States; Harvard Digestive Disease Center, Harvard Medical School, Boston, United States
Steen H Hansen
Division of Gastroenterology, Nutrition and Hepatology, Boston Children’s Hospital, Boston, United States; Department of Pediatrics, Harvard Medical School, Boston, United States; Harvard Digestive Disease Center, Harvard Medical School, Boston, United States
Cammie F Lesser
Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Cambridge, United States; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, United States
Hao Wu
Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States; Program in Cellular and Molecular Medicine, Boston Children’s Hospital, Boston, United States
Clara Abraham
Department of Medicine, Yale University, New Haven, United States
Division of Gastroenterology, Nutrition and Hepatology, Boston Children’s Hospital, Boston, United States; Department of Pediatrics, Harvard Medical School, Boston, United States; Harvard Digestive Disease Center, Harvard Medical School, Boston, United States
Homeostasis at mucosal surfaces requires cross-talk between the environment and barrier epithelial cells. Disruption of barrier function typifies mucosal disease. Here we elucidate a bifunctional role in coordinating this cross-talk for the inflammatory bowel disease risk-gene INAVA. Both activities require INAVA’s DUF3338 domain (renamed CUPID). CUPID stably binds the cytohesin ARF-GEF ARNO to effect lateral membrane F-actin assembly underlying cell-cell junctions and barrier function. Unexpectedly, when bound to CUPID, ARNO affects F-actin dynamics in the absence of its canonical activity as a guanine nucleotide-exchange factor. Upon exposure to IL-1β, INAVA relocates to form cytosolic puncta, where CUPID amplifies TRAF6-dependent polyubiquitination and inflammatory signaling. In this case, ARNO binding to CUPID negatively-regulates polyubiquitination and the inflammatory response. INAVA and ARNO act similarly in primary human macrophages responding to IL-1β and to NOD2 agonists. Thus, INAVA-CUPID exhibits dual functions, coordinated directly by ARNO, that bridge epithelial barrier function with extracellular signals and inflammation.